β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

featureCounts: an efficient general purpose program for assigning sequence reads to genomic features

Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

Sorafenib in advanced hepatocellular carcinoma

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Systemic treatment of hepatocellular carcinoma: the times they are a-changin’

Campani, C., & Nault, J. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-412 · Cited by 5

Current Immunotherapy Strategies and Emerging Biomarkers for the Treatment of Hepatocellular Carcinoma

Kapelanski‐Lamoureux, A., Lazaris, A., Meti, N., & Metrakos, P. P. (2025) · Cancers · doi:10.3390/cancers17233870 · Cited by 5

Matrine improves the hepatic microenvironment and reverses epithelial-mesenchymal transition in hepatocellular carcinoma by inhibiting the Wnt-1/β-catenin signaling pathway.

Shi, J., Zhang, H., Han, G., Wang, J., Han, X., Zhao, M., Duan, X., Mi, L., Li, N., Yin, X., et al. (2023) · PubMed Central · Cited by 4

Recurrence Pattern Is an Independent Surgical Prognostic Factor for Long-Term Oncological Outcomes in Patients with Hepatocellular Carcinoma

Hsu, H.-Y., Tang, J., Huang, S.-F., Huang, C.-W., Lin, S., Huang, S.-W., Lee, C., Wu, T., & Yu, M. (2024) · Biomedicines · doi:10.3390/biomedicines12030655 · Cited by 5

Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts

Weinfurtner, K. M., Tischfield, D. J., McClung, G., Brain, J. A., Gordan, J. D., Jiao, J., Furth, E. E., Li, W., Supan, E. T., Nadolski, G., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101264 · Cited by 4

Identification of prognostic tumor microenvironment in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors

Chen, S., Zhao, L., Wu, Z., Cai, H., Wang, F., Wu, L., Sun, H., & Guo, W. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113662 · Cited by 4

β-Catenin regulates distinct pathways from YAP and suppresses ONECUT1 to drive hepatoblastoma development in mice and humans

Liao, W., Zhang, Y., Wang, J., Cui, G., Evert, M., Xu, M. J., Wu, Y., Wang, X., Deng, S., Song, X., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001280 · Cited by 4

Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma

Shao, Y., Wang, H., Hsu, H.-W., Wo, R. R., Cheng, A., & Hsu, C. (2025) · Biology Direct · doi:10.1186/s13062-025-00645-8 · Cited by 4

Inferring Drug–Gene Relationships in Cancer Using Literature-Augmented Large Language Models

Lai, Y.-J., Wang, L.-J., Yasaka, T. M., Shin, Y., Ning, M., Tan, Y., Shih, C.-H., Guo, Y., Chen, P.-Y., Galloway, H., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0030 · Cited by 4

A novel ferroptosis-related signature for predicting prognosis, immune characteristics, and treatment prediction in hepatocellular carcinoma

Wu, C., Chen, X., Zhang, Y., Du, Y., Xu, J., Peng, Y., Lu, L., Huang, J., & Huang, H. (2025) · PLoS ONE · doi:10.1371/journal.pone.0322158 · Cited by 4

Comparative analysis of S100A10 and S100A11 in MASLD and hepatic cancer development revealed a tumor suppressive role for S100A10

Delangre, E., de Sousa, M. C., Türkal, M., Gjorgjieva, M., Chartier, S., Arnoux, G., Sobolewski, C., Fournier, M., Maeder, C., Rubbia‐Brandt, L., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07940-2 · Cited by 4

Pseudouridine synthase 1-targeted therapy activates antiviral immunity to boost cancer immunotherapy

Wang, F., Tong, Y., Guo, W., Qian, Y., Zhu, Z., Li, S., Li, L., Li, Q., Gao, W., & Liu, Y. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116233 · Cited by 4

Glutamine synthetase loss in β-catenin–mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming

Delgado, E. R., Patel, P., Tao, J., Krutsenko, Y., Liu, S., Green, D. M., Alzubali, R., Lehrich, B. M., Liu, J., Yasaka, T. M., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001591 · Cited by 5

Manipulating and tracking single hepatocyte behavior during mouse liver regeneration by performing hydrodynamic tail vein injection

Wang, S., de Galarreta, M. R., Sadler, K. C., & Lujambio, A. (2021) · STAR Protocols · doi:10.1016/j.xpro.2021.100440 · Cited by 4

Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma

Huang, J., Zhang, S., Yang, Y., Zhang, Z.-C., Jiang, N., Li, W.-C., Shen, J., Zhong, B., & Zhu, X. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221134832 · Cited by 4

Prediction of Prognosis, Immunotherapy and Chemotherapy with an Immune-Related Risk Score Model for Endometrial Cancer

Wei, W., Ye, B., Huang, Z., Mu, X., Qiao, J., Zhao, P., Jiang, Y., Wu, J., & Zhan, X. (2023) · Cancers · doi:10.3390/cancers15143673 · Cited by 4

Combination Immunotherapy of Oncolytic Flu-Vectored Virus and Programmed Cell Death 1 Blockade Enhances Antitumor Activity in Hepatocellular Carcinoma

Yu, H., Sun, F., Xu, Y., Yang, H., Tian, C., Li, C., Kang, Y., Lei, H. A. O., & Yang, P. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.150 · Cited by 4

Prediction of Efficacy for Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma with Hepatobiliary-Phase Gadolinium Ethoxybenzyl-Diethylenetriaminepentaacetic Acid MRI

Kunichika, H., Minamiguchi, K., Tachiiri, T., Shimizu, K., Taiji, R., Yamada, A., Nakano, R., Irizato, M., Yamauchi, S., Marugami, A., et al. (2024) · Cancers · doi:10.3390/cancers16122275 · Cited by 4

Advances in hepatocellular carcinoma drug resistance models

Xiang, Y., Wu, J., & Qin, H. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1437226 · Cited by 4

BATF2/SINHCAF regulates the quantity and function of macrophages infected with Mycobacterium Tuberculosis via regulation of TTC23 through Wnt/β-catenin pathway

Zhou, J., Xiong, K., Wang, H., Sun, W., Ke, H., Zhang, S., Dong, Z.-W., & Fan, L. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.138639 · Cited by 4

miR-3191 promotes the proliferation and metastasis of hepatocellular carcinoma via regulating PAK6

Xie, A., Wang, H., Huang, J., Sun, M., & Chen, L. (2024) · Infectious Agents and Cancer · doi:10.1186/s13027-024-00628-w · Cited by 4

T lymphocyte-based immune response and therapy in hepatocellular carcinoma: focus on TILs and CAR-T cells

Muhammed, T. M., Jasim, S. A., Zwamel, A. H., Rab, S. O., Ballal, S., Singh, A., Nanda, A., Ray, S., Hjazi, A. M., & Yasin, H. A. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04035-9 · Cited by 4

Bibliometric analysis of programmed cell death and immunogenic cell death in hepatocellular carcinoma immunotherapy: global trends and future directions

Chen, S.-P., & Tian, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-02278-9 · Cited by 4

TNFAIP2 deficiency drives formation of an immunosuppressive tumor microenvironment and confers resistance to anti-PD-1 therapy in skin cutaneous melanoma

Wang, Y., Wang, J., Chen, Z., Zhong, C., Luo, H., & Teng, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-10952-9 · Cited by 4

T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy

Kumar‐Sinha, C., & Sahai, V. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7097 · Cited by 4

T-Lymphocyte Gene-Regulated CCL5 and Its Association with Extrahepatic Metastasis in Hepatocellular Carcinoma

Dong, G., Fan, F., He, Y., Luo, Y., Yu, J., & Liang, P. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s420836 · Cited by 4

The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis

Peng, W., Pan, Y., Xie, L., Yang, Z., Ye, Z., Chen, J., Wang, J., Hu, D., Xu, L., Zhou, Z., et al. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241237631 · Cited by 5

Imaging for better responses to immunotherapy in hepatocellular carcinoma

Lindblad, K. E., & Lujambio, A. (2022) · Hepatology · doi:10.1002/hep.32627 · Cited by 4

Structure-Guided Optimization and Preclinical Evaluation of 6-O-Benzylguanine-Based Pin1 Inhibitor for Hepatocellular Carcinoma Treatment

Pu, W., Shen, X., Fan, X., Zheng, Y., Liu, X., Li, J., Zhou, J., He, J., Wei, R., Gong, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02144 · Cited by 3

ADVANCING CURCUMIN APPLICATIONS IN HEPATOCELLULAR CARCINOMA: INSIGHTS INTO PHARMACOKINETICS, PHARMACODYNAMICS AND NANODELIVERY SYSTEMS

MATE, R. T., Chivate, A. N., Jadhav, N. R., & Chivate, N. D. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i4.53730 · Cited by 3

Novel Therapeutics for Hepatocellular Carcinoma

Elsaid, M. I., & Manne, A. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.06.009 · Cited by 3

The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy

Wu, H., Shu, W., Ding, Y., Li, Q., Li, N., Wang, Q., Chen, Y., Han, Y., Huang, D., & Jiang, H. (2025) · BMC Cancer · doi:10.1186/s12885-025-14805-6 · Cited by 3

Hot and Cold HCC: Uncoupling Viral Oncogenesis and Therapy

Sneller, L., Mathur, K., Kottilil, S., & Mathur, P. (2025) · Viruses · doi:10.3390/v17091255 · Cited by 3

Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy

Yan, X., Xu, W., Yao, H., Wu, Z., Ning, J., Zhao, S., Liu, Y., Zhang, M., Xu, D., Shen, Z., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0649 · Cited by 3

Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma

Foerster, F., Wiesmann, L., Bark, P., & Galle, P. R. (2025) · Hepatology · doi:10.1097/hep.0000000000001554 · Cited by 3

Contrast-enhanced MRI for Hepatocellular Carcinoma Assessment: Advances in Contrast Agents and Immunotherapy

Xie, W., Sun, L., Fu, Y., Liu, Y., Wang, J., & Liu, L. (2025) · Academic Radiology · doi:10.1016/j.acra.2025.10.048 · Cited by 3

Targeting CXCR6 Disrupts β-Catenin Signaling and Enhances Sorafenib Response in Hepatocellular Carcinoma

Reeves, M. E., Chambers, A., Shrestha, A. P., Duarte, S., Zarrinpar, A., Malany, S., & Peddibhotla, S. (2025) · Cancers · doi:10.3390/cancers17233818 · Cited by 3

A deep learning radiopathomic signature predicts recurrence risk of hepatocellular carcinoma after hepatectomy

Wang, G., Chen, W., Liang, Z., Ding, F., Cui, J., Shen, Z., Lin, F., Li, X., Wang, X., & Zhao, X. (2026) · Communications Biology · doi:10.1038/s42003-026-09571-5 · Cited by 3

Neurotransmitters: Key regulators of the tumor immune microenvironment

Zhang, L., Jing, W., Li, Y., Ping, Y., & Zhang, Y. (2026) · Seminars in Immunology · doi:10.1016/j.smim.2026.102015 · Cited by 3

T Cell Exhaustion in Hepatocellular Carcinoma: A Substantial Barrier in Immunotherapy

Nouri, K., Aasadollahei, N., Haghir-Sharif-Zamini, Y., Seydi, H., Salehi, M., Mesdaghi, M., Najimi, M., & Vosough, M. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71044 · Cited by 5

Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma

Adán-Villaescusa, E., Castelló-Uribe, B., Uriarte, I., Santamaría, E., Barbero, R., Belzunce, M., López-Pascual, A., Latasa, M. U., Elurbide, J., Valbuena-Goiricelaya, E., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102717 · Cited by 3

Developing a prognostic model for hepatocellular carcinoma based on MED19 and clinical stage and determining MED19 as a therapeutic target

Jin, X., Zhang, Y., Hu, W., Liu, C., Cai, D., Sun, J., Wei, Q., & Cai, Q. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05978-x · Cited by 3

Carcinome hépatocellulaire : classifications histologiques et moléculaires

Bèaufrere, A., & Paradis, V. (2024) · Annales de Pathologie · doi:10.1016/j.annpat.2024.10.004 · Cited by 3

Targeting of COPⅠ elicits CD8+ T cell-mediated anti-tumor immunity and suppresses growth of intrahepatic cholangiocarcinoma

Chen, Z., Xu, G., Chen, X., Liu, Y., Yang, Z., Xiang, L., Zuo, Y., Zheng, N., Ye, Z., Xu, W., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217786 · Cited by 3

Dual Facets of Wnt/β-Catenin Signaling in Hepatocellular Carcinoma: Implications for Tumor Phenotyping and Clinical Management

Gomez, R., Sanchez, M., & Lopez, E. (2023) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/7icrlme63l · Cited by 3

Immunotherapy in hepatocellular cancer

Fountzilas, C. K., Evans, R., Alaklabi, S., & Iyer, R. V. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2020.12.002 · Cited by 4

Derivation of a Novel CIHI in Patients with Lung Adenocarcinoma for Estimating Tumor Microenvironment and Clinical Prognosis

Zhou, L., Xu, G., Wang, L., Zhang, J., & Li, W. (2021) · Disease Markers · doi:10.1155/2021/4495489 · Cited by 3

Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma

Zhu, J. W., Han, T., Zhao, S., Zhu, Y., Ma, S., Xu, F., Bai, T., Tang, Y., Xu, Y., & Liu, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.933210 · Cited by 3

Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review

Меньшиков, К. В., Султанбаев, А. В., Мусин, Ш. И., Rakhmatullina, I. R., Menshikovа, I. A., Abdeev, R. R., Султанбаева, Н. И., Popova, E. V., & Serebrennikov, G. A. (2022) · Creative Surgery and Oncology · doi:10.24060/2076-3093-2022-12-2-139-150 · Cited by 4

Hepatic macrophage mediated immune response in liver steatosis driven carcinogenesis

Tu, T., Alba, M. M., Datta, A. A., Hong, H., Hua, B., Jia, Y., Khan, J., Nguyen, P., Niu, X., Pammidimukkala, P., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.958696 · Cited by 3

Design, synthesis, and biological evaluation of novel 8-substituted quercetin derivatives targeting the β‑catenin/B-cell lymphoma 9 interaction

Peng, X., Shen, L., Bao, Y., Liu, C., Chen, Q., Zhang, H., Li, J., & Zhang, Q. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129591 · Cited by 3

Tumor-Extrinsic Axl Expression Shapes an Inflammatory Microenvironment Independent of Tumor Cell Promoting Axl Signaling in Hepatocellular Carcinoma

Breitenecker, K., Heiden, D., Demmer, T., Weber, G., Primorac, A.-M., Hedrich, V., Ortmayr, G., Gruenberger, T., Starlinger, P. P., Herndler‐Brandstetter, D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084202 · Cited by 3

Phospholipid isotope tracing suggests β-catenin-driven suppression of phosphatidylcholine metabolism in hepatocellular carcinoma

Vansant-Webb, C. H., Low, H. K., Kuramoto, J., Stanley, C. E., Qiang, H., Su, A. Y., Ross, A. N., Cooper, C. G., Cox, J. E., Summers, S. A., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2024.159514 · Cited by 3

Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses

Wang, Y., Shang, P., Xu, C., Dong, W., Zhang, X., Xia, Y., Sui, C., & Yang, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1416295 · Cited by 3

Changes in Mutations of Cell-Free DNA and Liver Tumor Tissue in Patients with Advanced Hepatocellular Carcinoma before and after Introduction of Lenvatinib

Tsuruoka, M., Ninomiya, M., Inoue, J., Iwata, T., Sano, A., Sato, K., Onuki, M., Sawahashi, S., & Masamune, A. (2024) · Oncology · doi:10.1159/000540438 · Cited by 3

A Senescence-Associated Gene Signature for Prognostic Prediction and Therapeutic Targeting in Adrenocortical Carcinoma

Peng, H., Chen, Q., Ye, L., & Wang, W. (2025) · Biomedicines · doi:10.3390/biomedicines13040894 · Cited by 4

Molecular stratification of hepatocellular carcinoma by metabolic-signaling pathways guides precision immunotherapy and TACE therapy

Li, B., Xu, Y., Zhu, Y., Zhang, Y., Wu, Z., Luo, T., Zhang, L., Hu, W., & Yu, D. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0344 · Cited by 3

Profound tumor response to combined CTLA-4 and PD-1 inhibition in systemic fourth line therapy observed in a patient with hepatocellular carcinoma harboring SETD2 and LRP1B mutations

Reiter, F. P., Rau, M., Kunzmann, V., Kickuth, R., Klein, I., Neumann, O., Stenzinger, A., Schirmacher, P., & Geier, A. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1952-1233 · Cited by 3

Cancer-specific associations of driver genes with immunotherapy outcomePreprint

Jun, T. W., Qing, T., Dong, G., Signaevsky, M., Hopkins, J. F., Frampton, G. M., Albacker, L. A., Cordon‐Cardo, C., Samstein, R. M., Pusztai, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.16.155895 · Cited by 3

How CRISPR Is Revolutionizing the Generation of New Models for Cancer ResearchPreprint

Rivera, F. J. S., & Dow, L. E. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041384 · Cited by 4

Establishment of a murine hepatocellular carcinoma model by hydrodynamic injection and characterization of the immune tumor microenvironment

Repáraz, D., Casares, N., Fuentes, A., & Navarro, F. C. (2024) · Methods in cell biology · doi:10.1016/bs.mcb.2024.02.006 · Cited by 2

Evolutionary dynamics of recurrent hepatocellular carcinoma under divergent immune selection pressures

Chakravarthy, A., Pasini, E., Zhao, X., To, J. C., Shen, S. Y., Fischer, S. E., Ghanekar, A., Vogel, A., Grant, R. C., Knox, J. J., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1537087 · Cited by 2

Immune checkpoints in hepatocellular carcinoma and the challenges of therapeutic resistance

Tao, X., & Yang, X. (2025) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2025.2542137 · Cited by 3

Efficacy and safety of PD-1 inhibitors combined with anti-angiogenic agents in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis

Gao, J., Zong, D., He, Y., Xu, J., & He, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-04049-y · Cited by 3

Immunometabolic heterogeneity in hepatocellular carcinoma: Transforming cold tumors into hot tumors

Xu, Y., & Sun, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105123 · Cited by 2

Rewiring the tumor microenvironment in hepatocellular carcinoma: mechanism-driven integration of immunotherapy and locoregional strategies

Li, M., Song, W., Wu, Y., Lin, H., Liu, W., & Chi, J. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2025.57 · Cited by 2

VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment

Guo, J., Bhela, S., Sharma, M., Protti, G., Luoh, S.-M., Wang, S., Firmino, N. S., Dasoveanu, D., Chan, C. K., Ibarra-Lopez, V., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0836 · Cited by 2

Colitis-Associated Carcinoma: The Quintessential Epithelial Neoplasia Driven by Chronic Inflammation

Drage, M. G., & Mino-Kenudson, M. A. (2026) · Cells · doi:10.3390/cells15050481 · Cited by 2

Hepatoprotective role for ERMP1 in MASLD-driven hepatocarcinogenesis and β-catenin-mutated tumors

Gjorgjieva, M., de Sousa, M. C., Delangre, E., Abegg, D., Maeder, C., Fournier, M., Morin, N., Adibekian, A., Serra, F., Sempoux, C. L., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218427 · Cited by 2

New understanding of the molecular pathogenesis and therapeutic progress of hepatocellular carcinoma

Wang, W.-J., Yuan, H.-X., Xu, J.-Z., Wang, X.-D., Na, G.-W., He, K.-J., Sun, W., Li, R., Che, J., & Cheng, Y.-S. (2026) · Oncology Reviews · doi:10.3389/or.2026.1763632 · Cited by 2

Efferocytosis as a Metabolic Rheostat: The Metabolic Bridge connecting TKI-induced cell death to immune tolerance in hepatocellular carcinoma

Sheng, X., Wang, L., Shi, G., Li, Y., Wang, D., Wang, W., Du, Y., Wang, S., Mi, C., & Yang, H. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105355 · Cited by 2

Integrated genomic analyses identify oncogenic pathway interplay in hepatocarcinogenesis defining specific molecular subtypes

Pan, L., Hirsch, T., Fang, J., Seretny, A., Imbeaud, S., Jin, S., Gege, O. O., Rebouissou, S., Sidali, S., Ammiche, N., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73212-y · Cited by 1

Traditional Chinese medicine reverses immune checkpoint resistance through lactate metabolic reprogramming in hepatocellular carcinoma: Mechanisms and therapeutic implications

Liu, L., Wang, J., & Hu, K. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121885 · Cited by 2

Chaperone-mediated autophagy is a tumor-suppressive mechanism in hepatocellular carcinoma

Patel, K., Zapatería, B., Ledet, A. J., Hazaveh, S. S., Gjergjova, F., Diaz, A., Sidoli, S., Lujambio, A., Cuervo, A. M., Macián, F., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117390 · Cited by 3

Wnt/β-catenin signaling in hepatocellular carcinoma: a key player in resistance to targeted and immunotherapies

Park, C., Wong, T. L., & K, S. (2026) · Carcinogenesis · doi:10.1093/carcin/bgag040 · Cited by 3

Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors

Rai, C., Ruan, H., Li, X., Li, W., Jeong, H.-H., Song, C., Liu, P., Chang, Y., Fang, H., Udhaya Kumar., S., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02698-1 · Cited by 2

Immune-dominated cellular heterogeneity and stromal plasticity in keloid infiltrating and hypercellular zones revealed by single-cell RNA sequencing

Cao, Y., Duan, L., Lin, D. X., Liu, Y., 杨明子, Liu, Y., Xu, Y., Xu, Y., & 王连召 (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1873878 · Cited by 2

Case report: A case of heterogeneity of the antitumor response to immune checkpoint inhibitors in a patient with relapsed hepatocellular carcinoma

Bao, Y., Wen, L., Chen, W., Zhao, J., Yang, Y., Wei, T., Zhang, J., & Liang, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.899811 · Cited by 2

Perspective Chapter: Dendritic Cells in the Tumor Microenvironment

Jin, D., Font, L. F., & Flores, C. T. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.108586 · Cited by 2

Role of chemokines in the hepatocellular carcinoma microenvironment and their translational value in immunotherapy*

Wang, Y., Sun, M., Zhang, T., Feng, Y., Luo, X., Xie, M., Ji, X., Liu, D., Huang, W., & Xia, L. (2022) · Oncology and Translational Medicine · doi:10.1007/s10330-022-0556-6 · Cited by 2

Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression

Schafer, C. C., Jiang, J., Elsamanoudi, S. I., Nousome, D., Young, D., Song, Y., Sesterhenn, I. A., Chesnut, G. T., & Tan, S. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0463 · Cited by 2

Management of Hepatocellular Carcinoma: The East-West Difference

Feng, Y., & Chan, S. L. (2023) · Current Chinese Science · doi:10.2174/2210298103666230912143208 · Cited by 2

Enhancing the Treating Efficacy of Immunotherapy through the Restructure of Tumor Microenvironment

Gong, B., Jia, W., Zhou, Y., Xu, Y., Ya, W., & Gao, H. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300061 · Cited by 2

Identification of immune cell-related prognostic genes characterized by a distinct microenvironment in hepatocellular carcinoma

Li, M., Zheng, K.-F., & Qiu, Y. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i2.243 · Cited by 2

Efficacy and safety analysis of PD-1 combined with regorafenib in the treatment of advanced hepatocellular carcinoma

Dong, L. (2024) · American Journal of Translational Research · doi:10.62347/iihg2242 · Cited by 2

Assessment of the circulating levels of immune system checkpoint selected biomarkers in patients with lung cancer

Safizadeh, B., Sadeh, M., Robati, A. K., Riahi, T., & Tavakoli‐Yaraki, M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09971-y · Cited by 2

Insights from the bottom-up development of LGR5-targeting immunotherapeutics

Mueller, N., de la Roche, M., & de la Roche, M. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltaf017 · Cited by 2

Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in Cancer

Hu, J., Jin, M., Feng, W., Rausseo, B. N., Reuben, A., Ma, C., Lizee, G. A., & Li, F. (2025) · Vaccines · doi:10.3390/vaccines13050521 · Cited by 2

Etiology-based Molecular Characterization of Hepatocellular Carcinoma Reveals SQLE’s Contribution to Immunosuppressive Microenvironment

Yu, K., Zhong, Q., Zhang, J., & Huang, C. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096370558250514063841 · Cited by 2

Unlocking Wnt's weak spot: Glycosylated nanoalbumins to reignite immune responses in MSS-CRC

Wei, X. P., Zuo, M., Liang, Q., Zhang, S., Wang, J., Li, Z., Yang, W., Ma, F., He, W., & Liu, T. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101412 · Cited by 2

New Experimental Mouse Models to Evaluate the Role of Transforming Growth Factor‐Beta in Liver Tumorigenesis

Cantos‐Cortes, A., Amengual, J., Espinosa‐Sotelo, R., Bertrán, E., Vaquero, J., de Galarreta, M. R., Molina-Sánchez, P., Serrano, T., Ramos, E., Calvo, M., et al. (2025) · Liver International · doi:10.1111/liv.70351 · Cited by 2

Bioinformatics Analysis for Constructing a Six-Immune-Related Long Noncoding RNA Signature as a Prognostic Model of Hepatocellular Carcinoma

Wang, J., Jin, Z.-R., Wu, G., Wang, J.-L., Xu, B.-H., Zhu, H., Guo, Y., & Wen, Z. (2022) · BioMed Research International · doi:10.1155/2022/2093437 · Cited by 3

Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”

Nishida, N. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0324 · Cited by 2

NAPSB as a Predictive Marker for Prognosis and Therapy Associated with an Immuno-Hot Tumor Microenvironment in Hepatocellular CarcinomaPreprint

Zhao, Q., Ning, Y., Lin, K., Liu, X., Ding, Y., Jiang, X., Zhang, Z., Xuan, Y.-T., Liu, L., Wang, F., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1417814/v1 · Cited by 2

Rapid generation of precision preclinical cancer models using regulatable in vivo base editingPreprint

Katti, A., Foronda, M., Zimmerman, J., Zafra, M. P., Goswami, S., Gardner, E. E., Diaz, B. J., Simon, J. M., Wuest, A. N., Luan, W., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.03.502708 · Cited by 2

Self-supervised Benchmarking for scRNAseq ClusteringPreprint

Tyler, S. R., Schadt, E. E., & Guccione, E. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.07.548158 · Cited by 2

Emerging role of oncogenic ß-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinomaPreprint

Dantzer, C., Vaché, J., Brunel, A., Mahouche, I., Raymond, A., Dupuy, J., Petrel, M., Bioulac‐Sage, P., Perrais, D., Dugot‐Senant, N., et al. (2024) · eLife · doi:10.7554/elife.95191.1 · Cited by 2

Integrated combinatorial functional genomics and spatial transcriptomics of tumors decodes genotype to phenotype relationshipsPreprint

Breinig, M., Lomakin, A., Heidari, E., Ritter, M. A., Rukhovich, G. D., Böse, L., Butthof, L., Wendler-Link, L., Wiethoff, H., Poth, T., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.14.593940 · Cited by 2

Immune exclusion in hepatoblastoma: Is β-catenin to blame again?

Hirsch, T. Z. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.05.005 · Cited by 2

Targeting metalloproteases is a promising strategy to enhance immunotherapy responses by overcoming immune exclusion in hepatocellular carcinoma

Bárcena‐Varela, M., & Berraondo, P. (2024) · Gut · doi:10.1136/gutjnl-2023-331647 · Cited by 1

Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by β-Catenin Activation

Berraondo, P., Ochoa, M. C., Olivera, I., & Melero, I. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0696 · Cited by 34

Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers

Kwee, S. A., & Tiirikainen, M. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2020.124 · Cited by 24

IDDF2024-ABS-0079 Targeting STING pathway as a therapeutic strategy against β-catenin driven immune escape and resistance to anti-PD1 therapy in hepatocellular carcinoma

Zhang, Q., Bi, J., Yeung, O. W. H., Ding, T., Chan, W.-L., Zhu, Y., Liu, J., Ng, T., Ching, Y. P., & Man, K. (2024) · doi:10.1136/gutjnl-2024-iddf.168

Su1460 - Oncoprotein RBMY Facilitates the Development and Metastasis of Hepatocellular Carcinoma

Ni, Y., Chua, H., & Chang, M. (2018) · Gastroenterology · doi:10.1016/s0016-5085(18)33821-6

Extracellular Vesicle‐Based Therapeutic Targeting of β‐Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer

Matsuda, A., Ishiguro, K., Yan, I. K., & Patel, T. C. (2019) · Hepatology Communications · doi:10.1002/hep4.1311 · Cited by 60